Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated:  3/5/2018
Fox Chase Cancer Center - Cheltenham
mi
from
Philadelphia, PA
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated: 3/5/2018
Fox Chase Cancer Center - Cheltenham
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated:  3/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated: 3/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
A Feasibility Study for Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  3/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
A Feasibility Study for Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 3/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Understanding Mechanisms of Acquired Resistance to BIBW2992
Understanding Mechanisms of Acquired Resistance to BIBW2992
Status: Enrolling
Updated:  3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Understanding Mechanisms of Acquired Resistance to BIBW2992
Understanding Mechanisms of Acquired Resistance to BIBW2992
Status: Enrolling
Updated: 3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer
A Phase I/II Study of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation Preoperatively for Patients With Locally Advanced Esophageal Cancer
Status: Enrolling
Updated:  3/5/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer
A Phase I/II Study of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation Preoperatively for Patients With Locally Advanced Esophageal Cancer
Status: Enrolling
Updated: 3/5/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
A Study in Myeloproliferative Disorders
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Houston, TX
A Study in Myeloproliferative Disorders
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study in Myeloproliferative Disorders
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study in Myeloproliferative Disorders
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated:  3/5/2018
Montgomery Spine Center
mi
from
Montgomery, AL
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated: 3/5/2018
Montgomery Spine Center
mi
from
Montgomery, AL
Click here to add this to my saved trials
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated:  3/5/2018
Community Neurosurgery
mi
from
Indianapolis, IN
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated: 3/5/2018
Community Neurosurgery
mi
from
Indianapolis, IN
Click here to add this to my saved trials
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated:  3/5/2018
Maryland Spine and Brain
mi
from
Annapolis, MD
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated: 3/5/2018
Maryland Spine and Brain
mi
from
Annapolis, MD
Click here to add this to my saved trials
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated:  3/5/2018
Cary Orthopedics
mi
from
Cary, NC
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated: 3/5/2018
Cary Orthopedics
mi
from
Cary, NC
Click here to add this to my saved trials
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated:  3/5/2018
DFW Center for Spinal Disorders
mi
from
Fort Worth, TX
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated: 3/5/2018
DFW Center for Spinal Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated:  3/5/2018
Tallahassee Neurological Clinic
mi
from
Tallahassee, FL
MaxAn Post Market Surveillance Validation
A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate
Status: Enrolling
Updated: 3/5/2018
Tallahassee Neurological Clinic
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Washington,
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Boston, MA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
New York, NY
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Charleston, SC
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Weston, FL
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Weston, FL
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Atlanta, GA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Kansas City, KA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Burlington, MA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer
Status: Enrolling
Updated:  3/5/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer
Status: Enrolling
Updated: 3/5/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Beth Isreal Deaconess Medical Center
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Beth Isreal Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
Status: Enrolling
Updated:  3/5/2018
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
Status: Enrolling
Updated: 3/5/2018
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas
Status: Enrolling
Updated:  3/5/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas
Status: Enrolling
Updated: 3/5/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas
Status: Enrolling
Updated:  3/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas
Status: Enrolling
Updated: 3/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Health Literacy Interventions to Overcome Disparities in CRC Screening
Health Literacy Interventions to Overcome Disparities in CRC Screening
Status: Enrolling
Updated:  3/5/2018
LSU Health Sciences Center
mi
from
Shreveport, LA
Health Literacy Interventions to Overcome Disparities in CRC Screening
Health Literacy Interventions to Overcome Disparities in CRC Screening
Status: Enrolling
Updated: 3/5/2018
LSU Health Sciences Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated:  3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated: 3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated:  3/5/2018
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated: 3/5/2018
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated:  3/5/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated: 3/5/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated:  3/5/2018
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated: 3/5/2018
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated:  3/5/2018
Dan L. Duncan Cancer Center at Baylor College of Medicine
mi
from
Houston, TX
Letrozole in Preventing Breast Cancer in Postmenopausal Women
A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels
Status: Enrolling
Updated: 3/5/2018
Dan L. Duncan Cancer Center at Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Koning Breast Computed Tomography Guided Biopsy
Koning Breast CT-guided Biopsy Phase I Trial
Status: Enrolling
Updated:  3/5/2018
Elizabeth Wende Breast Care
mi
from
Rochester, NY
Koning Breast Computed Tomography Guided Biopsy
Koning Breast CT-guided Biopsy Phase I Trial
Status: Enrolling
Updated: 3/5/2018
Elizabeth Wende Breast Care
mi
from
Rochester, NY
Click here to add this to my saved trials
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate
Status: Enrolling
Updated:  3/6/2018
NYU Cancer Center
mi
from
New York, NY
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate
Status: Enrolling
Updated: 3/6/2018
NYU Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate
Status: Enrolling
Updated:  3/6/2018
Bellevue Hospital
mi
from
New York, NY
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate
Status: Enrolling
Updated: 3/6/2018
Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies
Status: Enrolling
Updated:  3/6/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies
Status: Enrolling
Updated: 3/6/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial
Status: Enrolling
Updated:  3/6/2018
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial
Status: Enrolling
Updated: 3/6/2018
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente - Fremont
mi
from
Fremont, CA
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente Fresno Medical Center
mi
from
Fresno, CA
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente Fresno Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials